HSTO News and Press, Histogen Inc. From 12/01/20

Micro-cap Histogen ([[HSTO]] +173.4%) after announcing preliminary week 18 results from its Phase 1b/2a trial evaluating HST-001 in androgenic alopecia (male pattern baldness).At the week 18 primary efficacy endpoint, patients treated with HST-001 demonstrated separation from placebo for...

HST-001 Demonstrated Separation from Placebo at Week 18 Primary Efficacy Endpoint Assessment HST-001 Found to be Safe and Well Tolerated w ith No Serious Adverse Events Week 26 Fina...

SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (Nasdaq: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today anno...

Histogen (HSTO) to sell ~2.52M common shares at $1.78375/share, in a registered direct offering priced at-the-market under Nasdaq rules, for gross proceeds of ~$4.5M.Concurrently, the company will issue unregistered five and one-half years warrants to purchase 1,892,088 common shares at $1.70...

SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (Nasdaq: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today anno...

Histogen (HSTO): Q3 GAAP EPS of -$0.27.Revenue of $0.49M (+58.1% Y/Y)Cash and cash equivalents of $6.6M.Press Release For further details see: Histogen reports Q3 results

Topline Data for HST-001 Phase 1b/2a Trial for Androgenic Alopecia in Men on Track for 4Q20 Received $2M Grant Award from the Department of Defense for Clinical Advancement of HST-003 for Cartilage Regeneration in the Knee Appointed Moya Daniels as Executive Vice Pre...

SAN DIEGO, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today an...

Histogen (HSTO) ticks 2% higher in premarket on light volume after announcing an agreement with Amerimmune to jointly develop emricasan a caspase inhibitor, for the treatment of COVID-19.Additionally, the FDA has signed-off Phase 1 study of emricasan in mild-COVID-19 patie...

Histogen Receive s IND A pproval from FDA to Initiate a Phase 1 Study of Emricasan in M ild-COVID - 19 Patients to Assess Safety and Tolerability Amerimmune to Lead Development Efforts of Emricasan in a ...